Name: Latest research reports of Divi's Laboratories Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 3
Author: BOB Capital Markets Ltd.

Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer

6373.0000 -89.50 (-1.38%)

NSE Nov 21, 2025 15:31 PM

28.62% Gain from 52W Low

Volume: 130.8K

Divi's Laboratories Ltd.

23 May 2022, 12:00AM

6373.00

-1.38%

Divi's Labs (HOLD): Strong all-round beat but growth unsustainable cut to HOLD

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Robust standalone Q4 revenue/EBITDA growth of 45%/57% YoY, ahead of consensus by 11%/17%

Number of FII/FPI investors decreased from 990 to 897 in Sep 2025 qtr